Travere Therapeutics Announces Topline Results From Ongoing Phase 1/2 COMPOSE Study Of Pegtibatinase In Classical Homocystinuria; Treatment With Highest Dose Pegtibatinase Led To 55% Mean Reduction In Total Homocysteine From Baseline